KOSDAQBiotech & Pharma014950

Samik Pharm

₩7,390▼ 0.27%2026-11-18 close
Market Cap
₩74.5B
Turnover
₩2.6B
Volume
360K
Shares out.
10.1M
PER
—
PBR
1.1×
EPS
-₩255
Dividend Yield
0.47%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩40 per share · Prices as of the 2026-11-18 close

01

Report overview

From Cardiovascular Generics Toward CMO and Injectable Platforms

Samik Pharm is building CMO and long-acting injectable platforms on a cardiovascular generics base. Revenue has risen for three straight quarters through Q3 2026, while operating losses have continued for two quarters.

  1. 1

    Revenue rose 7.5% to KRW 60 billion in 2025, but operating profit fell 11.0% to KRW 3.27 billion, and the company swung to a net loss attributable to controlling shareholders of KRW 755 million.

  2. 2

    The Q3 2026 operating loss of KRW 574 million marked a swing to a loss from a year earlier, and the net loss attributable to controlling shareholders over the last four quarters totals KRW 2.43 billion.

  3. 3

    The Re-Leap 2030 plan targets KRW 130 billion in revenue and KRW 11 billion in operating profit by 2030, with CMO and long-acting injectables as core pillars.

  4. 4

    A Thymosin alpha 1 long-acting formulation patent was registered on August 27, 2026, but commercialization still requires clinical and regulatory steps.

  5. 5

    A high controlling-shareholder stake leaves a small free float, and patent news has triggered sharp one-day share price moves, so supply and demand volatility is elevated.

02

Business structure

Samik Pharm is a mid-sized pharmaceutical company with more than 50 years of history that listed on KOSDAQ on October 27, 2025 through a merger with a SPAC. Most revenue comes from prescription drugs (ETC), which accounted for 86.0% of revenue in Q1 2026, while contract manufacturing (CMO) accounted for 11.4%.

By product, cardiovascular drugs, including antihypertensive and lipid-lowering agents, are the largest group at 46.8% of 2025 revenue, followed by diabetes drugs at 10.7%. The diabetes combination product Piocita entered reimbursement in November 2023 and is targeting wider hospital prescribing.

The CMO business highlights bulk production of metformin hydrochloride and a bilayer tablet formulation technology as its differentiators, and it is reported to be producing 32 items for 44 clients.

CMO revenue was KRW 6.8 billion in 2025, or 11.4% of the total, and tablet production rose from 271.54 million tablets in 2023 to 346.35 million in 2025. Over the same period, utilization rose from 63.1% to 80.6%.

Its drug-distribution subsidiary handles finished-product logistics, and the 2030 revenue mix target assigns it a 28% contribution. R&D is centered on long-acting injectables built on the in-house UniSphero microsphere platform.

The generics and CMO markets are competitive, and the company describes bulk production and specialty formulations as its niche.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩15.8B₩1.1B6.8%
2025Q4₩15.2B₩49,344,0900.3%
2026Q1₩15.5B₩900M6.0%
2026Q2₩15.7B-₩200M−1.4%
2026Q3₩16.4B-₩600M−3.5%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2024₩55.9B₩3.7B₩3.5B6.6%6.8%23.8%
2025₩60B₩3.3B-₩800M5.5%−1.1%23.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Revenue rose 7.5% to KRW 60 billion in 2025, while operating profit fell 11.0% to KRW 3.27 billion. As a result, the operating margin declined from 6.6% in 2024 to 5.5% in 2025. Net profit attributable to controlling shareholders swung from KRW 3.52 billion in 2024 to a net loss of KRW 755 million in 2025.

The company attributed the 2025 loss to a share-based compensation expense of KRW 3.97 billion linked to the SPAC merger, which was booked as other losses. Net income including non-controlling interests was also a loss of KRW 755 million in 2025.

Operating cash flow fell from KRW 438 million in 2024 to KRW 208 million in 2025. At the end of 2025, total equity was KRW 69 billion, all of it attributable to controlling shareholders, and total liabilities were KRW 16.2 billion. The debt-to-equity ratio edged down from 23.8% in 2024 to 23.5% in 2025.

On a quarterly basis, revenue moved from KRW 15.8 billion in Q3 2025 to KRW 15.2 billion in Q4 2025, a 3.6% quarter-on-quarter decline. It then rose to KRW 15.5 billion in Q1 2026, KRW 15.7 billion in Q2 2026 and KRW 16.4 billion in Q3 2026, marking three consecutive quarterly increases from Q1 to Q3 2026.

Q3 2026 revenue was up 3.6% from a year earlier. Operating profit went from KRW 1.07 billion in Q3 2025 to KRW 49.34 million in Q4 2025, a 95.4% drop. It recovered to KRW 929 million in Q1 2026, up 1,783.0% quarter on quarter, before turning to an operating loss of KRW 228 million in Q2 2026.

The operating loss widened to KRW 574 million in Q3 2026, and the company has posted losses for two consecutive quarters since Q2 2026. Net profit attributable to controlling shareholders was KRW 682 million in Q3 2025, then turned into a loss of KRW 3.34 billion in Q4 2025.

It turned positive at KRW 1.24 billion in Q1 2026, then returned to losses of KRW 77.46 million in Q2 2026 and KRW 254 million in Q3 2026. The net loss attributable to controlling shareholders over the last four quarters totals KRW 2.43 billion.

In its October 30, 2026 investor relations material, the company cited higher advertising costs of KRW 1.05 billion, personnel costs of KRW 840 million and inventory valuation provisions of KRW 640 million as temporary cost increases that weighed on 2026 operating profit.

05

Industry analysis

The domestic pharmaceutical industry faces continued pressure from drug price cuts, which has made portfolio diversification a key challenge. An industry observer has described Samik Pharm as shifting from a traditional generics company toward a platform and CMO business.

The CMO market is viewed as highly competitive, and the company is targeting a niche by mass-producing products such as metformin hydrochloride, where low margins have created outsourcing demand. It is also pursuing wider CMO orders based on its bilayer tablet formulation technology.

In long-acting injectables, it is compared with KOSDAQ peers that promote their own platforms, such as Peptron. Hana Securities analyzed the company's long-acting injectable platform and CMO capabilities as medium-term growth drivers in a June 2026 report.

A May 2026 report said the company planned to add medical device manufacturing and sales to its business purpose at an extraordinary shareholder meeting, as part of diversification.

Entry by existing device makers and other pharmaceutical companies is already under way, so the choice of strategy was flagged as a key issue. At KRW 60 billion in 2025 revenue, the scale gap with large contract development and manufacturing companies is wide.

06

Outlook

In its Re-Leap 2030 medium-term vision, the company set targets of KRW 130 billion in revenue and KRW 11 billion in operating profit by 2030, implying average annual growth of 17.2% through 2030.

Its five core strategies are a stronger sales force using contract sales organizations, launch of a fixed-dose combination antihypertensive, expansion of CMO revenue, upgrading the long-acting injectable platform, and business diversification through subsidiaries.

The 2030 revenue mix target assigns 25% to the core generics business, 18% to contract sales, 13% to improved combination drugs, 16% to CMO and 28% to the drug-distribution subsidiary.

According to investor relations materials, a first-generic product is scheduled for launch in November 2027, an improved combination drug in April 2028, and another first-generic product in November 2028. A P-CAB class product was reported to have received marketing approval in early 2026.

One analysis cited a target of starting operations at a GSP-compliant logistics center in Q1 2027. A patent for a long-acting microsphere formulation of Thymosin alpha 1 was registered on August 27, 2026, and the company plans to apply the technology to other peptide drugs.

Patent registration does not by itself mean commercial launch or confirmed clinical efficacy, and follow-on development and clinical and regulatory steps remain. The long-acting injectable SLIM2401 was scheduled for a non-clinical pharmacokinetic study in the second half of 2026.

Because the company said first-half 2026 operating profit declined due to growth investments, the timing of any profit recovery depends on new product launches and the trend in CMO utilization.

07

Valuation

PER
—
PBR
1.1×
ROE
-3.8%
EPS
-₩255
BPS
₩7,629
Dividend per share
₩40

Because the company has recorded net losses attributable to controlling shareholders over the last four quarters, its PER cannot be calculated, so asset-based metrics are the main reference points.

The price-to-book ratio shows the share price relative to the KRW 69 billion of equity attributable to controlling shareholders at year-end 2025, a modest premium to net asset value.

Total equity and controlling-shareholder equity were the same KRW 69 billion at year-end 2025, so there is no non-controlling interest in the capital structure. The 2025 dividend payout ratio was 25%, and total cash dividends rose 28.6% from the prior year to KRW 367.78 million.

The company stated that it qualifies as a high-dividend company under the Restriction of Special Taxation Act. Dividend yield moves with the share price, so the trend in total dividends and payout ratio is the more stable reference.

On days when patent news emerged, the share price moved sharply within a single session, and some analysts attribute this to a low free float caused by the high controlling-shareholder stake.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Revenue up for three straight quarters

Revenue rose for three consecutive quarters from Q1 to Q3 2026, and Q3 2026 revenue of KRW 16.4 billion was up 3.6% from a year earlier. Q1 2026 revenue of KRW 15.5 billion was reported as up 10.4% year on year. Top-line growth has continued, and whether it converts into profit is the next test.

Rising CMO output and utilization

Tablet output rose from 271.54 million in 2023 to 346.35 million in 2025, and utilization climbed from 63.1% to 80.6%. The company reports producing 32 items for 44 clients under a made-to-order model that it says carries low inventory and disposal risk. The 2030 target assigns 16% of revenue to CMO.

Long-acting injectable platform and patents

A Thymosin alpha 1 long-acting microsphere patent registered on August 27, 2026 was introduced as a formulation that substantially reduces dosing frequency. The company plans to apply the technology to other peptide drugs. Its in-house UniSphero platform supports a diversified pipeline that includes the obesity candidate SLIM2403.

09

Bear factors

Weaker profitability and loss-making quarters

Operating profit fell 11.0% to KRW 3.27 billion in 2025, and the operating margin dropped to 5.5%. Operating losses continued in Q2 and Q3 2026, and the net loss attributable to controlling shareholders over the last four quarters totals KRW 2.43 billion. The Q3 2026 operating loss of KRW 574 million was a swing to loss from a year earlier.

One-off costs and investment burden

The company cited advertising costs of KRW 1.05 billion, personnel costs of KRW 840 million and inventory provisions of KRW 640 million as temporary cost increases behind the 2026 profit decline. Facility investment and R&D spending have grown since the listing, raising the fixed cost burden. Whether revenue growth outpaces these costs is the key variable.

Time required before new products contribute

Patent registration for Thymosin alpha 1 does not confirm a commercial product or clinical efficacy. Launches are planned for November 2027, April 2028 and November 2028, so profit contribution is still some way off. Generic price competition under drug price pressure adds to the burden.

10

Risk factors

Earnings structure

Operating losses have continued through Q2 and Q3 2026, and the loss-making quarters are accumulating. Revenue has grown, but selling costs and one-off charges have offset it. Reaching the 2030 operating profit target requires a structural shift in profitability.

Drug pricing and regulation

Domestic drug price adjustments and generic price competition could pressure unit prices. Delays in approvals or launches would push back the 2030 target path. Long-acting injectables require clinical and regulatory steps, so development timelines are long.

Governance and supply-demand

A high controlling-shareholder stake leaves a small free float, and patent news has triggered sharp one-day share moves. The SPAC merger listing and the 2025 share-based compensation expense can complicate the reading of earnings. The timing of lock-up releases is another source of supply-demand swings.

11

What to watch next

  1. Q1 2027

    This is the target start of operations for the GSP-compliant logistics center. It is the point at which the effect of bringing logistics costs in-house should show up in operating expenses.

  2. Around March 2027

    This is the expected filing window for the 2026 annual report, based on the 2025 report filed on March 20, 2026. The annual operating margin and CMO revenue share are the next items to check.

  3. November 2027

    This is the planned launch date for a first-generic product in the investor relations plan. It marks when the core generics business would begin to add revenue from a new product.

  4. April 2028

    This is the planned launch of the improved combination drug. It ties to whether the 13% combination-product share in the 2030 revenue target can be achieved.

12

Overall view

Samik Pharm's revenue, built on cardiovascular prescription drugs and its CMO business, has risen for three consecutive quarters from Q1 to Q3 2026.

Annual revenue reached KRW 60 billion in 2025, up 7.5%, but operating profit fell 11.0% to KRW 3.27 billion, and profit attributable to controlling shareholders swung to a net loss of KRW 755 million.

Operating losses continued in Q2 and Q3 2026, and the net loss attributable to controlling shareholders over the last four quarters totals KRW 2.43 billion. Bullish factors include top-line growth, higher CMO capacity and utilization, and the registration of a long-acting injectable patent.

Bearish factors include weaker profitability, temporary cost increases and the long lead time before new products launch. The 2030 targets of KRW 130 billion in revenue and KRW 11 billion in operating profit are medium-term goals the company has presented, not confirmed forecasts.

The next checkpoints are the start of logistics center operations in Q1 2027 and the annual operating margin in the 2026 annual report, expected around March 2027. With no PER available, valuation discussion centers on asset-based metrics and the dividend trend.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. medipana.com
  2. leadeconomy.co.kr
  3. todaymild.com
  4. m.dailypharm.com
  5. dailypharm.com
  6. comp.fnguide.com
  7. m.dailypharm.com
  8. dailypharm.com
  9. dailymedi.com
  10. butler.works
  11. news.nate.com
  12. thedailymoney.com
  13. digitaltoday.co.kr
  14. newspim.com
  15. fnnews.com
  16. job-post.co.kr
  17. hitnews.co.kr
  18. medicaltimes.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis